New stock news | Shimai Pharmaceutical's Hong Kong IPO prospectus is invalidated
Zhejiang Shimei Pharmaceutical Co., Ltd.-B's Hong Kong Stock Offering Document has expired for 6 months.
Zhejiang Shimai Pharmaceutical Co., Ltd.-B (referred to as Shimai Pharmaceutical) submitted a listing prospectus for Hong Kong stocks on November 12, 2025, which expired on May 12, 2026, after 6 months, with Huatai International as its exclusive sponsor.
According to the prospectus, Shimai Pharmaceutical was established in 2017 and is a pioneer and global leading enterprise in the next-generation T-cell engager (TCE) therapy. TCEs are bispecific or multispecific antibodies designed to target tumor cells by binding to tumor-associated antigens (TAAs) on the tumor cells and receptors on T cells, thereby directing them to the tumor tissue and activating T cells to induce targeted cytotoxic effects. The company early on recognized the differentiation potential of TCEs, which are a next-generation immunotherapy aimed at harnessing and guiding the body's immune system to fight cancer.
Related Articles
HK Stock Market Move | Shenzhen Han's CNC Technology (03200) rose more than 3% on the AI PCB driving performance increase. The company is expected to benefit from the expansion of leading PCB factories.
HK Stock Market Move | Pork concept fell the most, Muyuan's April pork price fell below cost line, institutions pointed out that the expectation of capacity digestion has strengthened.
ServiceNow(NOW.US) plans to issue $4 billion in bonds to replace short-term loans and support the expansion of its billion-dollar AI business.
HK Stock Market Move | Shenzhen Han's CNC Technology (03200) rose more than 3% on the AI PCB driving performance increase. The company is expected to benefit from the expansion of leading PCB factories.
HK Stock Market Move | Pork concept fell the most, Muyuan's April pork price fell below cost line, institutions pointed out that the expectation of capacity digestion has strengthened.
ServiceNow(NOW.US) plans to issue $4 billion in bonds to replace short-term loans and support the expansion of its billion-dollar AI business.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
